Prognosis in UC After First Biological

To study the long-term clinical outcome of patients with ulcerative colitis treated with first trial of biological therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ulcerative Colitis Colitis Colitis, Ulcerative Colonic Diseases Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Diseases Intestinal Diseases

Age range

16 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

UC patients treated with at least one biological in Tampere University Hospital between January 2009 and January 2020 were identified and reviewed from patient records.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients treated for ulcerative colitis for the first trial of biological

Exclusion criteria

Age under 16 years

Treatment and study plan

infliximab, adalimumab, golimumab, vedolizumab, ustekinumab

Biological

Other names: small molecules

Primary outcomes

Response to treatment

Time frame: within 5 years

Need for colectomy or enhancement of treatment within follow-up
Side-effects

Time frame: within 5 years

treatment related side-effects reported

Sponsors and collaborators

Lead sponsor

Tampere University Hospital

Other

Registry information

Official study title

The Long-term Outcome of Patients With Ulcerative Colitis Treated With First Trial of Biological.

Acronym: biological

Important dates

Study start: 2009
Primary completion: 2020
Study completion: 2022
First posted: Sep 7, 2022
Registry last updated: Sep 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed